Warby Parker Inc. (WRBY) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Warby Parker Inc. (WRBY) stock forecast summary
Our AI ranks Warby Parker Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Warby Parker Inc. is a mid-cap company with a market capitalization of $3.28B. It ranks number 4 by market capitalization among the 8 Ophthalmic Goods issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for WRBY is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, WRBY included.
Follow WRBY freeWRBY price chart and AI forecast
How WRBY ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Warby Parker Inc. (WRBY) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Ophthalmic Goods peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
Valuation & Market
| Metric | WRBY | Rank |
|---|---|---|
| Market Cap | $3.28B | 4/8 |
| P/E Ratio | 423.42x | – |
| P/B Ratio | 9.26x | 1/7 |
| EPS | $0.06 | – |
| Book Value/Share | $2.86 | – |
| Revenue/Share | $7.37 | – |
| FCF/Share | $0.18 | – |
Profitability & Margins
| Metric | WRBY | Rank |
|---|---|---|
| ROIC | 0.3% | 5/6 |
| Gross Margin | 54.6% | 5/6 |
| Operating Margin | 0.2% | 5/6 |
| EBT Margin | 1.1% | 4/6 |
| Tax Rate | 21.9% | – |
Financial Health
| Metric | WRBY | Rank |
|---|---|---|
| Current Ratio | 2.27x | 4/7 |
| Quick Ratio | 2.01x | 4/7 |
| D/E Ratio | 0.93x | 3/7 |
| Financial Leverage | 1.93x | 3/7 |
| Interest Coverage | 40.6x | 1/6 |
| Working Capital | $207M | 5/7 |
Cash Flow
| Metric | WRBY | Rank |
|---|---|---|
| Operating Cash Flow | $95M | 5/8 |
| Free Cash Flow | $22M | 4/6 |
| Capital Spending | -$74M | 3/6 |
| OCF Growth YoY | -18.3% | – |
| FCF Growth YoY | -58.5% | – |
| FCF/Sales | 2.4% | 4/6 |
| CapEx/Sales | 8.1% | 2/6 |
Operational Efficiency
| Metric | WRBY | Rank |
|---|---|---|
| Asset Turnover | 1.34x | 1/7 |
| Receivables Turnover | 438.3x | 1/7 |
| Inventory Turnover | 9.8x | 1/6 |
| Fixed Assets Turnover | 4.5x | 5/7 |
| Days Sales Outstanding | 1 days | 7/7 |
| Days Inventory | 37 days | 6/6 |
| Payables Period | 36 days | 4/5 |
| Cash Conversion Cycle | 2 days | 5/5 |
Income Statement
| Metric | WRBY | Rank |
|---|---|---|
| Total Revenue | $911M | 4/7 |
| Operating Income | $1M | 6/7 |
| SG&A Expense | $497M | 4/7 |
| Cost of Goods Sold | $413M | 4/7 |
Dividend & Shareholder Information
| Metric | WRBY | Rank |
|---|---|---|
| Shares Outstanding | 124M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $371M | 54.3% of assets |
| Cash & Short-term Investments | $293M | 42.9% of assets |
| Accounts Receivable | $2M | 0.3% of assets |
| Inventory | $42M | 6.2% of assets |
| Total Liabilities | $329M | 48.1% of assets |
| Short-term Debt | $122M | 17.9% of assets |
WRBY quarterly financials and insider trading
Warby Parker Inc. (WRBY) industry peers
Companies classified under the same SEC industry code as Warby Parker Inc. (Ophthalmic Goods): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| WRBY Warby Parker Inc. | ▲ | $3.28B |
| ALC Alcon Inc | ▼ | $30.71B |
| COO Cooper Companies, Inc. | ▼ | $10.38B |
| BLCO Bausch & Lomb Corp | ▶ | $5.65B |
| EYE National Vision Holdings, Inc. | ▼ | $1.35B |
| STAA Staar Surgical Co | ▶ | $1.08B |
| RXST Rxsight, Inc. | ▲ | $188M |
| LUCY Innovative Eyewear Inc | ▲ | $7M |
Where WRBY sits on the market map
Warby Parker Inc. (WRBY) stock news
Loading...
Warby Parker Inc. (WRBY) stock forecast FAQ
What is the Warby Parker Inc. (WRBY) stock forecast?
Our AI ranks Warby Parker Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Warby Parker Inc. stock predictions?
A per-ticker accuracy statistic for WRBY is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Warby Parker Inc. forecasts updated?
Warby Parker Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Warby Parker Inc.'s industry peers?
8 issuers in our coverage, WRBY included, share the SEC industry code Ophthalmic Goods. The largest are: Alcon Inc (ALC), Cooper Companies, Inc. (COO), Bausch & Lomb Corp (BLCO), National Vision Holdings, Inc. (EYE), Staar Surgical Co (STAA), Rxsight, Inc. (RXST).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.